Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label
incidence of BRCA1/2, PALB2, PTEN, PALB2 mutations
1) Determine the incidence of the BRCA1/2, PALB2, PTEN, PALB2 mutations in patients having at diagnosis a non metastatic triple negative breast cancer
up to 1 month
No
Jean-Marc EXTRA, MD
Principal Investigator
Institut Paoli-Calmettes
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
SA03/IPC 2010-003
NCT01434420
March 2011
March 2019
Name | Location |
---|